Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Small-molecule inhibition of BRDT for male contraception.

Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE.

Cell. 2012 Aug 17;150(4):673-84.

2.
3.

Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage.

Suarez-Alvarez B, Morgado-Pascual JL, Rayego-Mateos S, Rodriguez RM, Rodrigues-Diez R, Cannata-Ortiz P, Sanz AB, Egido J, Tharaux PL, Ortiz A, Lopez-Larrea C, Ruiz-Ortega M.

J Am Soc Nephrol. 2017 Feb;28(2):504-519. doi: 10.1681/ASN.2015080910. Epub 2016 Jul 19.

PMID:
27436852
4.

Parsing the potential of a new male contraceptive.

Wolgemuth DJ, Griswold MD, Grimes DA.

Nat Med. 2012 Oct;18(10):1466-7. doi: 10.1038/nm.2970. No abstract available.

PMID:
23042348
5.

Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.

Jung M, Philpott M, Müller S, Schulze J, Badock V, Eberspächer U, Moosmayer D, Bader B, Schmees N, Fernández-Montalván A, Haendler B.

J Biol Chem. 2014 Mar 28;289(13):9304-19. doi: 10.1074/jbc.M113.523019. Epub 2014 Feb 4.

6.

BET bromodomain inhibition of MYC-amplified medulloblastoma.

Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher SE, Zeid R, Masoud S, Yu F, Vue N, Gibson WJ, Paolella BR, Mitra SS, Cheshier SH, Qi J, Liu KW, Wechsler-Reya R, Weiss WA, Swartling FJ, Kieran MW, Bradner JE, Beroukhim R, Cho YJ.

Clin Cancer Res. 2014 Feb 15;20(4):912-25. doi: 10.1158/1078-0432.CCR-13-2281. Epub 2013 Dec 2.

7.

Insights into role of bromodomain, testis-specific (Brdt) in acetylated histone H4-dependent chromatin remodeling in mammalian spermiogenesis.

Dhar S, Thota A, Rao MR.

J Biol Chem. 2012 Feb 24;287(9):6387-405. doi: 10.1074/jbc.M111.288167. Epub 2012 Jan 3.

8.

Inhibition of the acetyl lysine-binding pocket of bromodomain and extraterminal domain proteins interferes with adipogenesis.

Goupille O, Penglong T, Kadri Z, Granger-Locatelli M, Fucharoen S, Maouche-Chrétien L, Prost S, Leboulch P, Chrétien S.

Biochem Biophys Res Commun. 2016 Apr 15;472(4):624-30. doi: 10.1016/j.bbrc.2016.03.013. Epub 2016 Mar 10.

PMID:
26972250
9.

Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.

Horne GA, Stewart HJ, Dickson J, Knapp S, Ramsahoye B, Chevassut T.

Stem Cells Dev. 2015 Apr 1;24(7):879-91. doi: 10.1089/scd.2014.0302. Epub 2014 Dec 17.

10.

Brdt Bromodomains Inhibitors and Other Modern Means of Male Contraception.

Zdrojewicz Z, Konieczny R, Papier P, Szten F.

Adv Clin Exp Med. 2015 Jul-Aug;24(4):705-14. doi: 10.17219/acem/33827. Review.

11.

Design and characterization of bivalent BET inhibitors.

Tanaka M, Roberts JM, Seo HS, Souza A, Paulk J, Scott TG, DeAngelo SL, Dhe-Paganon S, Bradner JE.

Nat Chem Biol. 2016 Dec;12(12):1089-1096. doi: 10.1038/nchembio.2209. Epub 2016 Oct 24.

12.

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice.

Lee DU, Katavolos P, Palanisamy G, Katewa A, Sioson C, Corpuz J, Pang J, DeMent K, Choo E, Ghilardi N, Diaz D, Danilenko DM.

Toxicol Appl Pharmacol. 2016 Jun 1;300:47-54. doi: 10.1016/j.taap.2016.03.013. Epub 2016 Apr 11.

PMID:
27078884
13.

Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.

Qi J.

Cold Spring Harb Perspect Biol. 2014 Dec 1;6(12):a018663. doi: 10.1101/cshperspect.a018663. Review.

14.

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS.

Cell. 2011 Sep 16;146(6):904-17. doi: 10.1016/j.cell.2011.08.017. Epub 2011 Sep 1.

15.

The first bromodomain of the testis-specific double bromodomain protein Brdt is required for chromocenter organization that is modulated by genetic background.

Berkovits BD, Wolgemuth DJ.

Dev Biol. 2011 Dec 15;360(2):358-68. doi: 10.1016/j.ydbio.2011.10.005. Epub 2011 Oct 12.

16.

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK.

Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17.

17.

BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.

Wang B, Zhang M, Takayama T, Shi X, Roenneburg DA, Kent KC, Guo LW.

EBioMedicine. 2015 Sep 28;2(11):1650-61. doi: 10.1016/j.ebiom.2015.09.045. eCollection 2015 Nov.

18.

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.

Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, Sure U, Fleischhack G, Eggert A, Schulte JH.

Oncotarget. 2013 Nov;4(11):2080-95.

19.

The role of the double bromodomain-containing BET genes during mammalian spermatogenesis.

Berkovits BD, Wolgemuth DJ.

Curr Top Dev Biol. 2013;102:293-326. doi: 10.1016/B978-0-12-416024-8.00011-8. Review.

20.

Cooperative binding of two acetylation marks on a histone tail by a single bromodomain.

Morinière J, Rousseaux S, Steuerwald U, Soler-López M, Curtet S, Vitte AL, Govin J, Gaucher J, Sadoul K, Hart DJ, Krijgsveld J, Khochbin S, Müller CW, Petosa C.

Nature. 2009 Oct 1;461(7264):664-8. doi: 10.1038/nature08397.

PMID:
19794495

Supplemental Content

Support Center